SCHEMBL31460309

SCHEMBL31460309

CCOC(=O)c1c(N)sc2c(O)c(Br)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 1.00
▸ MEN1 O00255 7/20 1.00
▸ KMT2A Q03164 7/20 1.00
▸ GAA P10253 4/20 1.00
▸ ALOX15 P16050 3/20 1.00
▸ TSHR P16473 2/20 1.00
▸ USP2 O75604 1/20 0.75
▸ NPSR1 Q6W5P4 2/20 0.73
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ MAPK1 P28482 2/20 0.55
▸ ALDH1A1 P00352 9/20 0.53
▸ HPGD P15428 5/20 0.53
▸ FHIT P49789 1/20 0.49
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ GRM6 O15303 4/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ MCL1 Q07820 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31459922 0.84 MAPT (0.73) MAPTMEN1KMT2AGAAALOX15
SCHEMBL31459864 0.80 KMT2A (1.00) MAPTMEN1KMT2AGAAALOX15
SCHEMBL15172955 0.80 KMT2A (1.00) MAPTMEN1KMT2AGAAALOX15
SCHEMBL3984848 0.80 MAPT (0.67) MAPTMEN1KMT2AGAAALOX15
SCHEMBL2925906 0.78 TSHR (0.67) MAPTMEN1KMT2AGAAALOX15
SCHEMBL3990578 0.78 MAPT (0.64) MAPTMEN1KMT2AGAAALOX15
SCHEMBL16521093 0.78 MAPT (0.78) MAPTMEN1KMT2AGAAALOX15
SCHEMBL15184999 0.78 MAPT (0.78) MAPTMEN1KMT2AGAAALOX15
SCHEMBL2308619 0.75 MAPT (0.60) MAPTMEN1KMT2AGAAALOX15
SCHEMBL24683238 0.73 MAPT (0.57) MAPTMEN1KMT2AGAAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors ENANTA PHARMACEUTICALS, INC. 2025-05-15 — — US disclosed
WO-2025090868-A1 PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2025-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154163-A1 Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors HSD17B13, HSD17B1, HSD11B1 MAPT 3628/4885MEN1 1840/4885KMT2A 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback